<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110625</url>
  </required_header>
  <id_info>
    <org_study_id>SYN20/04</org_study_id>
    <nct_id>NCT05110625</nct_id>
  </id_info>
  <brief_title>mHealth Intervention to Prevent Type 2 Diabetes Mellitus (Pilot Study)</brief_title>
  <acronym>preDIABETEXT</acronym>
  <official_title>Development and Evaluation of a Low Intensity, Multifaceted, Digital Health Intervention to Prevent Type 2 Diabetes Mellitus in the Primary Care Setting: the PREDIABETEXT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació d'investigació Sanitària de les Illes Balears</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació d'investigació Sanitària de les Illes Balears</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop and evaluate a low intensity, multifaceted, digital&#xD;
      health intervention to prevent T2DM based on: i) the use of a system comprising mobile health&#xD;
      (mHealth) technology integrated with electronic health records to send tailored text messages&#xD;
      (SMSs) promoting lifestyle changes in people at risk of T2DM, and, ii) the provision of&#xD;
      online education to primary healthcare workers about prediabetes management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PREDIABETEXT project will involve five WorkPackages (WP). In WP1-4 we will develop and&#xD;
      pilot-test the different components of the intervention (WP1 will develop the brief text&#xD;
      messages targeted to patients; WP2 will adapt our existing technology system to deliver the&#xD;
      messages; WP3 will develop an educational intervention targeted to Primary Healthcare&#xD;
      workers, and; WP4 will pilot-test and optimise both interventions). In WP5 we will conduct a&#xD;
      phase II, six-month, three-arm, cluster randomised, clinical trial with 42 primary care&#xD;
      workers and 420 patients at risk of T2DM (HbA1c from 6% to 6.4% or fasting plasma glucose&#xD;
      110-125mg/dl, or both) registered in Primary Care centres from Mallorca. Patients will be&#xD;
      allocated to a control (usual care) group, intervention A (patient messaging intervention),&#xD;
      or intervention B (patient messaging intervention plus online education to their primary&#xD;
      healthcare workers). The primary outcome will be HbA1c. Secondary outcomes will include&#xD;
      additional clinical outcomes, and physiological, behavioural and psychological outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Glycated Hemoglobin (HbA1C) at 6 months</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief motivation questionnaire (ad hoc)</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>On a scale from 0 to 7, this questionnaire meassures the level of motivation that participants present for following a healthy diet and a physical activity plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14-point Mediterranean diet adherence screener (MEDAS-14)</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>Adherence to healthy diet. The score ranges from 0 to 14. A higher score corresponds to a higher adherence to Mediterranean diet. We will classify participants as low adherents (≤5), moderate adherents (6-9) or high adherents (≥10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REGICOR Short form Physical Activity Questionnaire</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>The questionnaire is a reliable and valid method to estimate moderate and vigorous intensity leisure time physical activity and sensitive to detect changes in moderate and vigorous intensity leisure time physical activity https://regicor.cat/aplicacions/activitat-fisica/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spanish version of the physical activity questionnaire used in the Physical activity questionnaire from the Nurses' Health Study</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>We will use the second part of the questionnaire, which studies sedentary behaviour. It includes questions about the number of hours spent in sedentary activities.&#xD;
Public Health Nutrition: 8(7), 920-927 https://nurseshealthstudy.org/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Adult Tobbacco Survey: GATS questionnaire.</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>Tobbacco consumption. 3-items adapted from the GATS questionnaire (WHO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of alcohol consumption - FISTERRA</measure>
    <time_frame>Baseline and Postintervention (6 months)</time_frame>
    <description>Calcultaion of alcohol consumption in Spanish Standard Drink units (10g per unit) per week.&#xD;
https://www.fisterra.com/herramientas/calcumed/</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Intervention A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Messaging Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive messaging intervention plus online education to their primary healthcare workers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive usual care only, and their healthcare workers will not receive online education</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>preDIABE-TEXT</intervention_name>
    <description>Participants will receive text messages (three per week) in their mobile phones during six months.</description>
    <arm_group_label>Intervention A</arm_group_label>
    <arm_group_label>Intervention B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online Education</intervention_name>
    <description>Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.</description>
    <arm_group_label>Intervention B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ELIGIBILITY CRITERIA FOR PRIMARY HEALTHCARE WORKERS:&#xD;
&#xD;
        We will include physicians and nurses from primary care centres in Mallorca. We will&#xD;
        exclude those anticipating moving to a different centre during the study period.&#xD;
&#xD;
        ELIGIBILITY CRITERIA FOR PATIENTS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Registered in the Public Health Service of the Balearic Islands&#xD;
&#xD;
          -  At risk of T2DM (HbA1c from 6% to 6.4% or fasting plasma glucose 110-125mg/dl, or&#xD;
             both)&#xD;
&#xD;
          -  With access to a mobile device able toreceive text messages.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18 years old or older than 75 years old&#xD;
&#xD;
          -  People not able to read messages in Spanish&#xD;
&#xD;
          -  Patients with severe mental conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ignacio Ricci-Cabello</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Balearic Islands</state>
        <zip>07002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, Casamitjana R, Castaño L, Castell C, Catalá M, Delgado E, Franch J, Gaztambide S, Girbés J, Gomis R, Gutiérrez G, López-Alba A, Martínez-Larrad MT, Menéndez E, Mora-Peces I, Ortega E, Pascual-Manich G, Rojo-Martínez G, Serrano-Rios M, Valdés S, Vázquez JA, Vendrell J. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012 Jan;55(1):88-93. doi: 10.1007/s00125-011-2336-9. Epub 2011 Oct 11.</citation>
    <PMID>21987347</PMID>
  </reference>
  <reference>
    <citation>Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, Jan S, Graves N, de Keizer L, Barry T, Bompoint S, Stepien S, Whittaker R, Rodgers A, Thiagalingam A. Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29;314(12):1255-63. doi: 10.1001/jama.2015.10945. Erratum in: JAMA. 2016 Mar 8;315(10):1057.</citation>
    <PMID>26393848</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetic State</keyword>
  <keyword>Glycemic Control</keyword>
  <keyword>Telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share all collected IPD after anonymization</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available from January 2023 onwards</ipd_time_frame>
    <ipd_access_criteria>Upon a reasonable request, we will grant access to public organizations. The PI of the project will review the requests.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

